PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19032736-9 2008 In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. Cisplatin 92-101 thymoma viral proto-oncogene 1 Mus musculus 40-43 19032736-9 2008 In the in vivo study, blocking the PI3K/Akt cascade with LY294002 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice, suppressing half the tumor growth with cisplatin alone. Cisplatin 190-199 thymoma viral proto-oncogene 1 Mus musculus 40-43 18364504-7 2008 CCR7 stimulation protected metastatic SCCHN cells from cisplatin-induced apoptosis in an Akt-dependent manner. Cisplatin 55-64 thymoma viral proto-oncogene 1 Mus musculus 89-92 17504983-0 2007 Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Cisplatin 47-56 thymoma viral proto-oncogene 1 Mus musculus 88-91 18046317-0 2008 The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Cisplatin 81-90 thymoma viral proto-oncogene 1 Mus musculus 36-39 18046317-8 2008 Our results suggest that the PI3K-gamma-Akt pathway lessens apoptosis and plays a critical role in the maintenance of renal function in cisplatin-induced acute kidney injury. Cisplatin 136-145 thymoma viral proto-oncogene 1 Mus musculus 40-43 34381726-7 2021 Animal experiments showed that TPL, particularly TPL + cisplatin (DDP), significantly reduced the tumor burden, prolonged the life span of mice by inhibiting M2 macrophage polarization, and downregulated the levels of CD31 and CD206 (CD31 is the vascular marker and CD206 is the macrophage marker), the mechanism of which may be related to the inhibition of the PI3K/Akt/NF-kappaB signaling pathway. Cisplatin 55-64 thymoma viral proto-oncogene 1 Mus musculus 367-370 16396982-3 2006 Blocking the PI3K/Akt cascade with a PI3K inhibitor (wortmannin) increased the efficacy of cisplatin-induced inhibition of intraabdominal dissemination and production of ascites in athymic nude mice inoculated ip with the Caov-3 human ovarian cancer cell line. Cisplatin 91-100 thymoma viral proto-oncogene 1 Mus musculus 18-21 11850823-8 2002 Investigation of TC21"s effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt. Cisplatin 129-138 thymoma viral proto-oncogene 1 Mus musculus 263-266 34671212-0 2021 Long non-coding RNA MEG3 promotes cisplatin-induced nephrotoxicity through regulating AKT/TSC/mTOR-mediated autophagy. Cisplatin 34-43 thymoma viral proto-oncogene 1 Mus musculus 86-89 34671212-5 2021 In both in vitro and in murine models of DDP-induced nephrotoxicity, lnc-MEG3 exacerbated DDPIN by negatively regulating miRNA-126 subsequently causing a decreased AKT/TSC/mTOR-mediated autophagy. Cisplatin 41-44 thymoma viral proto-oncogene 1 Mus musculus 164-167 11331275-9 2001 In contrast to vitamin D(3), cisplatin and etoposide down-regulated Akt levels only modestly, did not promote significant loss of MEK expression, and did not up-regulate MEKK-1. Cisplatin 29-38 thymoma viral proto-oncogene 1 Mus musculus 68-71 34580062-8 2021 Ectopic PLCB1 induced resistance to treatment with gemcitabine combined with cisplatin, which could be reversed by the AKT inhibitor MK2206. Cisplatin 77-86 thymoma viral proto-oncogene 1 Mus musculus 119-122 34268902-13 2021 RESULTS: Cisplatin reduced protein level of IGF-1 by about 85% compared with the vehicle group and also reduced IGF-1/PI3K/Akt signalling in skeletal muscle. Cisplatin 9-18 thymoma viral proto-oncogene 1 Mus musculus 123-126 34268902-15 2021 The administration of a combination of cisplatin and IGF-1 significantly suppressed the cisplatin-induced downregulation of IGF-1/PI3K/Akt signalling and upregulation of MuRF1 and atrogin-1 (up to 1.6 +- 0.3 and 1.5 +- 0.4 folds, P < 0.001, respectively), resulting in diminished muscular atrophy. Cisplatin 39-48 thymoma viral proto-oncogene 1 Mus musculus 135-138 34268902-15 2021 The administration of a combination of cisplatin and IGF-1 significantly suppressed the cisplatin-induced downregulation of IGF-1/PI3K/Akt signalling and upregulation of MuRF1 and atrogin-1 (up to 1.6 +- 0.3 and 1.5 +- 0.4 folds, P < 0.001, respectively), resulting in diminished muscular atrophy. Cisplatin 88-97 thymoma viral proto-oncogene 1 Mus musculus 135-138 34381726-7 2021 Animal experiments showed that TPL, particularly TPL + cisplatin (DDP), significantly reduced the tumor burden, prolonged the life span of mice by inhibiting M2 macrophage polarization, and downregulated the levels of CD31 and CD206 (CD31 is the vascular marker and CD206 is the macrophage marker), the mechanism of which may be related to the inhibition of the PI3K/Akt/NF-kappaB signaling pathway. Cisplatin 66-69 thymoma viral proto-oncogene 1 Mus musculus 367-370 35548339-1 2022 Acquired cisplatin resistance in cervical cancer therapy is principally caused by reduction in intracellular drug accumulation, which is exerted by hyperactivation of the oncogenic PI3K/Akt signaling axis and overexpression of cisplatin-exporter MRP2 along with prosurvival effectors NF-kappaB and IAPs in cervical cancer cells. Cisplatin 9-18 thymoma viral proto-oncogene 1 Mus musculus 186-189 34077275-12 2021 These results indicate that resveratrol upregulates miR-455-5p to target PTEN and activate the PI3K-Akt signaling pathway to counteract cisplatin ototoxicity. Cisplatin 136-145 thymoma viral proto-oncogene 1 Mus musculus 100-103 34461812-8 2021 We used western blotting analysis to demonstrate that R-Rg3 restored cisplatin-induced AKI might be related to PI3K/AKT and NF-(Formula: see text)B mediated apoptosis and inflammation pathways. Cisplatin 69-78 thymoma viral proto-oncogene 1 Mus musculus 116-119 32252554-4 2020 Our findings showed that CuB treatment with cisplatin reduced cell proliferation, and reduced tumor development through activating apoptosis and autophagy via PI3K/AKT/mTOR signaling pathway. Cisplatin 44-53 thymoma viral proto-oncogene 1 Mus musculus 164-167 35530288-13 2022 As such, beta-elemene acted as an inhibitor of PI3K/AKT/mTOR signaling and enhanced the anticancer effect of cisplatin by targeting tumor metabolism, chemoresistance, and stem-like behavior. Cisplatin 109-118 thymoma viral proto-oncogene 1 Mus musculus 52-55 35210433-9 2022 Finally, mechanistic studies showed that upregulation of the PI3K/Akt signaling pathway by c-Myb contributed to the increased HC survival after cisplatin exposure in vitro. Cisplatin 144-153 thymoma viral proto-oncogene 1 Mus musculus 66-69 33272245-0 2020 MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway. Cisplatin 78-87 thymoma viral proto-oncogene 1 Mus musculus 112-115 33227065-7 2020 It was further demonstrated that loss of function of AKT1 isoform is associated with reduced sensitivity towards cisplatin treatment in triple-negative breast cancers cellular and syngeneic mice models. Cisplatin 113-122 thymoma viral proto-oncogene 1 Mus musculus 53-57 33227065-8 2020 The decrease in cisplatin treatment response in shAKT1 cells was allied with the upregulation in the expression of transporter protein ABCG2, whereas silencing of ABCG2 restored cisplatin sensitivity in these cells through AKT/SNAIL/ABCG2 axis. Cisplatin 16-25 thymoma viral proto-oncogene 1 Mus musculus 50-53 33227065-8 2020 The decrease in cisplatin treatment response in shAKT1 cells was allied with the upregulation in the expression of transporter protein ABCG2, whereas silencing of ABCG2 restored cisplatin sensitivity in these cells through AKT/SNAIL/ABCG2 axis. Cisplatin 178-187 thymoma viral proto-oncogene 1 Mus musculus 50-53 33227065-9 2020 In conclusion, our study demonstrated the varied expression of AKT isoforms in triple-negative breast cancers and also confirmed differential role of isoforms in stemness, invasiveness and response towards the cisplatin treatment. Cisplatin 210-219 thymoma viral proto-oncogene 1 Mus musculus 63-66 35174550-8 2022 In conclusion, maltol exerted the protective effects against cisplatin-induced cardiotoxicity, at least partially by inhibiting the activation of PI3K/Akt signaling pathways in cardiomyocytes, to ease oxidative stress, and alleviate reactive oxygen species-mediated apoptosis. Cisplatin 61-70 thymoma viral proto-oncogene 1 Mus musculus 151-154 35281608-0 2022 Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells In Vitro and In Vivo through Inhibiting the PI3K/AKT/mTOR/NF-kappaB Signaling Pathway. Cisplatin 55-64 thymoma viral proto-oncogene 1 Mus musculus 147-150 35281608-8 2022 FJD cotreatment increased the efficacy of cisplatin, including inhibiting OC cell proliferation and invasion, promoting cell apoptosis, and inhibiting the PI3K/AKT/mTOR signaling pathway, while this enhancement was suppressed by IGF-1. Cisplatin 42-51 thymoma viral proto-oncogene 1 Mus musculus 160-163 35281608-10 2022 Conclusions: This study indicated that FJD could improve the efficacy of cisplatin by inhibiting the PI3K/AKT/mTOR/NF-kappaB signaling pathway. Cisplatin 73-82 thymoma viral proto-oncogene 1 Mus musculus 106-109 35236823-11 2022 Furthermore, considering that indirect HIF inhibitors are effective in clinical cancer therapy, we treated tumor-bearing BALB/c mice with STAT3 and PI3K/AKT inhibitors and found that the dual-targeting strategy sensitized breast cancer to cisplatin. Cisplatin 239-248 thymoma viral proto-oncogene 1 Mus musculus 153-156 35210433-0 2022 c-Myb protects cochlear hair cells from cisplatin-induced damage via the PI3K/Akt signaling pathway. Cisplatin 40-49 thymoma viral proto-oncogene 1 Mus musculus 78-81 33390985-0 2020 Linalool Prevents Cisplatin Induced Muscle Atrophy by Regulating IGF-1/Akt/FoxO Pathway. Cisplatin 18-27 thymoma viral proto-oncogene 1 Mus musculus 71-74 32150448-0 2020 Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity. Cisplatin 76-85 thymoma viral proto-oncogene 1 Mus musculus 53-56 32280245-10 2020 Results: Cisplatin attenuated the promoting capacity of CAFs on lung cancer cell migration and invasion, via suppressing CAFs" effect on metastasis-related genes including Twist1, vascular endothelial growth factor receptor (VEGFR), MMP2, and AKT signaling pathway. Cisplatin 9-18 thymoma viral proto-oncogene 1 Mus musculus 243-246 32280245-12 2020 KRT8 upregulation in CAFs is responsible for the inhibitory effect of cisplatin on lung cancer cells metastasis potential through AKT pathway suppression. Cisplatin 70-79 thymoma viral proto-oncogene 1 Mus musculus 130-133 32280245-15 2020 Conclusion: Our results revealed a novel mechanism that cisplatin attenuated the metastasis promoting effect of CAFs via KRT8/AKT signaling pathway. Cisplatin 56-65 thymoma viral proto-oncogene 1 Mus musculus 126-129 31961716-9 2020 Considering the known roles of some cell survival pathways in antagonizing insults, we examined the levels of the PDE4-associated proteins Sirt1, PI3K, and phosphorylated AKT in cisplatin-treated renal tubular cells with or without cilomilast treatment. Cisplatin 178-187 thymoma viral proto-oncogene 1 Mus musculus 171-174 31320816-0 2019 Squalene attenuates the oxidative stress and activates AKT/mTOR pathway against cisplatin-induced kidney damage in mice. Cisplatin 80-89 thymoma viral proto-oncogene 1 Mus musculus 55-58 32039764-0 2020 Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. Cisplatin 57-66 thymoma viral proto-oncogene 1 Mus musculus 111-114 31781349-0 2019 Remote Ischemic Preconditioning Protects Cisplatin-Induced Acute Kidney Injury through the PTEN/AKT Signaling Pathway. Cisplatin 41-50 thymoma viral proto-oncogene 1 Mus musculus 96-99 31320816-10 2019 It may be suggested that squalene ameliorated the cisplatin-induced histopathological damages in the kidney through activation of AKT/mTOR signaling pathway by regulating the balance of the redox system due to its antioxidative effect. Cisplatin 50-59 thymoma viral proto-oncogene 1 Mus musculus 130-133 30975980-0 2019 Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression. Cisplatin 48-57 thymoma viral proto-oncogene 1 Mus musculus 0-3 29556279-0 2018 HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-kappaB signaling pathway. Cisplatin 31-40 thymoma viral proto-oncogene 1 Mus musculus 105-108 30387162-0 2019 TLR2 protects cisplatin-induced acute kidney injury associated with autophagy via PI3K/Akt signaling pathway. Cisplatin 14-23 thymoma viral proto-oncogene 1 Mus musculus 87-90 30387162-5 2019 Therefore, we propose that cisplatin might activate TLR2, which subsequently phosphorylates PI3K/Akt, leading to enhanced autophagy of renal tubular epithelial cells and protecting cisplatin-induced AKI. Cisplatin 27-36 thymoma viral proto-oncogene 1 Mus musculus 97-100 30387162-9 2019 Mechanistically, TLR2 inhibited autophagy via activating PI3K/Akt signaling pathway in renal tubular epithelial cells after the cisplatin treatment. Cisplatin 128-137 thymoma viral proto-oncogene 1 Mus musculus 62-65 30387162-10 2019 Take together, these results suggest that TLR2 may protect cisplatin-induced AKI by activating autophagy via PI3K/Akt signaling pathway. Cisplatin 59-68 thymoma viral proto-oncogene 1 Mus musculus 114-117 30374107-0 2018 The protective effects of maltol on cisplatin-induced nephrotoxicity through the AMPK-mediated PI3K/Akt and p53 signaling pathways. Cisplatin 36-45 thymoma viral proto-oncogene 1 Mus musculus 100-103 30235825-0 2018 Platycodon grandiflorum Saponins Ameliorate Cisplatin-Induced Acute Nephrotoxicity through the NF-kappaB-Mediated Inflammation and PI3K/Akt/Apoptosis Signaling Pathways. Cisplatin 44-53 thymoma viral proto-oncogene 1 Mus musculus 136-139 29110119-0 2018 Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. Cisplatin 57-66 thymoma viral proto-oncogene 1 Mus musculus 102-105 29284644-8 2018 The combination of PTUPB and cisplatin increased apoptosis and decreased phosphorylation in the MAPK/ERK and PI3K/AKT/mTOR pathways compared with controls. Cisplatin 29-38 thymoma viral proto-oncogene 1 Mus musculus 114-117 30121639-14 2018 Platelets rescued the inhibition of cell proliferation and angiogenesis and protected against cell apoptosis induced by cisplatin, platelets rescued cisplatin-induced apoptosis via the Akt/Bad/Bcl-2 signaling pathway under endoplasmic reticulum stress. Cisplatin 120-129 thymoma viral proto-oncogene 1 Mus musculus 185-188 30121639-14 2018 Platelets rescued the inhibition of cell proliferation and angiogenesis and protected against cell apoptosis induced by cisplatin, platelets rescued cisplatin-induced apoptosis via the Akt/Bad/Bcl-2 signaling pathway under endoplasmic reticulum stress. Cisplatin 149-158 thymoma viral proto-oncogene 1 Mus musculus 185-188 27799485-9 2017 Together, these results reveal a pathway consisting of PKCdelta, AKT, mTOR, and ULK1 that inhibits autophagy in cisplatin nephrotoxicity. Cisplatin 112-121 thymoma viral proto-oncogene 1 Mus musculus 65-68 28762162-12 2017 The decreased Akt, p70S6 kinase, and Foxo3a phosphorylation observed with cisplatin treatment was significantly recovered by treadmill exercise in both the muscles. Cisplatin 74-83 thymoma viral proto-oncogene 1 Mus musculus 14-17 27799485-5 2017 In vitro, pharmacologic inhibition of mTOR, directly or through inhibition of AKT, enhanced autophagy after cisplatin treatment. Cisplatin 108-117 thymoma viral proto-oncogene 1 Mus musculus 78-81 28255274-5 2017 Mechanistically, a heightened ER stress and a reduced Akt activity were observed in kidney tissues of HHcy mice after cisplatin injection. Cisplatin 118-127 thymoma viral proto-oncogene 1 Mus musculus 54-57 27799485-6 2017 Notably, in both cells and kidneys, blockade of PKCdelta suppressed the cisplatin-induced phosphorylation of AKT, mTOR, p70S6 kinase, and ULK1 resulting in upregulation of autophagy. Cisplatin 72-81 thymoma viral proto-oncogene 1 Mus musculus 109-112 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 92-101 thymoma viral proto-oncogene 1 Mus musculus 72-75 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 92-101 thymoma viral proto-oncogene 1 Mus musculus 146-149 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 249-258 thymoma viral proto-oncogene 1 Mus musculus 72-75 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 249-258 thymoma viral proto-oncogene 1 Mus musculus 146-149 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 249-258 thymoma viral proto-oncogene 1 Mus musculus 72-75 27799485-8 2017 In mechanistic studies, we showed coimmunoprecipitation of PKCdelta and AKT from lysates of cisplatin-treated cells and direct phosphorylation of AKT at serine-473 by PKCdeltain vitro Finally, administration of the PKCdelta inhibitor rottlerin with cisplatin protected against cisplatin nephrotoxicity in wild-type mice, but not in renal autophagy-deficient mice. Cisplatin 249-258 thymoma viral proto-oncogene 1 Mus musculus 146-149 27825756-0 2016 Carvacrol attenuates acute kidney injury induced by cisplatin through suppression of ERK and PI3K/Akt activation. Cisplatin 52-61 thymoma viral proto-oncogene 1 Mus musculus 98-101 26656301-0 2015 Cisplatin Induces Overactivation of the Dormant Primordial Follicle through PTEN/AKT/FOXO3a Pathway which Leads to Loss of Ovarian Reserve in Mice. Cisplatin 0-9 thymoma viral proto-oncogene 1 Mus musculus 81-84 27876874-8 2016 TWIST1, in part via GAS6 and L1CAM, led to higher expression and activation of Akt upon cisplatin treatment, and inhibition of Akt activation sensitized cells to cisplatin. Cisplatin 88-97 thymoma viral proto-oncogene 1 Mus musculus 79-82 27876874-8 2016 TWIST1, in part via GAS6 and L1CAM, led to higher expression and activation of Akt upon cisplatin treatment, and inhibition of Akt activation sensitized cells to cisplatin. Cisplatin 162-171 thymoma viral proto-oncogene 1 Mus musculus 79-82 27876874-8 2016 TWIST1, in part via GAS6 and L1CAM, led to higher expression and activation of Akt upon cisplatin treatment, and inhibition of Akt activation sensitized cells to cisplatin. Cisplatin 162-171 thymoma viral proto-oncogene 1 Mus musculus 127-130 26882203-0 2016 Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. Cisplatin 19-28 thymoma viral proto-oncogene 1 Mus musculus 86-89 26882203-6 2016 Importantly, analysis of the PTEN/AKT/FOXO3a pathway demonstrated that melatonin significantly decreased the cisplatin-mediated inhibitory phosphorylation of PTEN, a key negative regulator of dormant follicle activation. Cisplatin 109-118 thymoma viral proto-oncogene 1 Mus musculus 34-37 26882203-7 2016 Moreover, melatonin prevented the cisplatin-induced activating phosphorylation of AKT, GSK3beta, and FOXO3a, all of which trigger follicle activation. Cisplatin 34-43 thymoma viral proto-oncogene 1 Mus musculus 82-85 26656301-12 2015 This study is the first to show the involvement of the PTEN/Akt/FOXO3 pathway in premature ovarian failure after cisplatin treatment and the possibility of rescue through in vitro maturation. Cisplatin 113-122 thymoma viral proto-oncogene 1 Mus musculus 60-63 26656301-5 2015 In this study, we investigated the role of PTEN/Akt/FOXO3 pathway in cisplatin-induced primordial follicle depletion. Cisplatin 69-78 thymoma viral proto-oncogene 1 Mus musculus 48-51 26656301-9 2015 The activation of the PTEN/Akt/FOXO3 pathway cascade increased cytoplasmic translocation of FOXO3a in cisplatin-treated follicles, which in turn increased the pool size of growing follicles, and rapidly depleted the number of dormant follicles. Cisplatin 102-111 thymoma viral proto-oncogene 1 Mus musculus 27-30 25282897-7 2014 Along with the increase of the concentration of cisplatin and Buzhong Yiqi decoction, the expressions of PI3K and AKT gradually reduced. Cisplatin 48-57 thymoma viral proto-oncogene 1 Mus musculus 114-117 26136189-6 2015 RESULTS: Tumour implantation and cisplatin induced muscle atrophy by activating pro-inflammatory cytokines, p38-C/EBP-beta, and myostatin, and by down-regulating Akt, myoD, and myogenin, leading to activation of ubiquitin-proteasome-mediated proteolysis and muscle weakness. Cisplatin 33-42 thymoma viral proto-oncogene 1 Mus musculus 162-165 25978595-0 2015 Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. Cisplatin 53-62 thymoma viral proto-oncogene 1 Mus musculus 127-130 25978595-6 2015 Moreover, LQ/CDDP combination led to the downregulation of protein expression of MMP-2/9, PI3 K, p-AKT, and upregulated PTEN protein level that play an important role in tumor metastasis progression. Cisplatin 13-17 thymoma viral proto-oncogene 1 Mus musculus 99-102 25071019-5 2014 Mechanistically, AuNPs prevent cisplatin-induced activation of Akt and NF-kB signaling axis in ovarian cancer cells that are critical for EMT, stem cell maintenance and drug resistance. Cisplatin 31-40 thymoma viral proto-oncogene 1 Mus musculus 63-66 24823295-10 2014 Furthermore, the mRNA levels of myostatin and p21 were significantly upregulated by the administration of cisplatin, compared to DR. On the other hand, the phosphorylation of Akt and FOXO3a, which leads to the blockade of the upregulation of MuRF1 and MAFbx, was significantly and dramatically decreased by cisplatin. Cisplatin 106-115 thymoma viral proto-oncogene 1 Mus musculus 175-178 24823295-10 2014 Furthermore, the mRNA levels of myostatin and p21 were significantly upregulated by the administration of cisplatin, compared to DR. On the other hand, the phosphorylation of Akt and FOXO3a, which leads to the blockade of the upregulation of MuRF1 and MAFbx, was significantly and dramatically decreased by cisplatin. Cisplatin 307-316 thymoma viral proto-oncogene 1 Mus musculus 175-178 25282897-10 2014 CONCLUSION: Among nude mice with lung adenocarcinoma transplantation tumor, the PI3K and AKT protein and gene expressions in spleen, stomach and lung tissues increased, which might indicated the effect of cisplatin and Buzhong Yiqi decoction in reducing PI3K and AKT expressions and the relations between the reduction degree and the concentrations of Buzhong Yiqi decoction. Cisplatin 205-214 thymoma viral proto-oncogene 1 Mus musculus 89-92 25282897-10 2014 CONCLUSION: Among nude mice with lung adenocarcinoma transplantation tumor, the PI3K and AKT protein and gene expressions in spleen, stomach and lung tissues increased, which might indicated the effect of cisplatin and Buzhong Yiqi decoction in reducing PI3K and AKT expressions and the relations between the reduction degree and the concentrations of Buzhong Yiqi decoction. Cisplatin 205-214 thymoma viral proto-oncogene 1 Mus musculus 263-266 25282897-11 2014 Cisplatin combined with Buzhong Yiqi decoction could decrease the PI3K and AKT protein and gene expression in spleen, stomach and lung, and make the pathway closer to normal, so as to protect the functions of spleen, stomach and lung, there may be target spots of Buzhong Yiqi decoction in PI3K/AKT signal pathway. Cisplatin 0-9 thymoma viral proto-oncogene 1 Mus musculus 75-78 25282897-11 2014 Cisplatin combined with Buzhong Yiqi decoction could decrease the PI3K and AKT protein and gene expression in spleen, stomach and lung, and make the pathway closer to normal, so as to protect the functions of spleen, stomach and lung, there may be target spots of Buzhong Yiqi decoction in PI3K/AKT signal pathway. Cisplatin 0-9 thymoma viral proto-oncogene 1 Mus musculus 295-298 24130050-0 2013 Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma. Cisplatin 24-33 thymoma viral proto-oncogene 1 Mus musculus 73-76 24130050-8 2013 Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr. Cisplatin 26-35 thymoma viral proto-oncogene 1 Mus musculus 210-213 24130050-8 2013 Tunicamycin combined with cisplatin (CDDP) inhibited proliferating cell nuclear antigen (PCNA) expression and increased the cleavage of PARP; this effect was partially rescued by the overexpression of ABCG2 or Akt-myr. Cisplatin 37-41 thymoma viral proto-oncogene 1 Mus musculus 210-213 22760211-0 2012 Concurrent blockade of NF-kappaB and Akt pathways potentiates cisplatin"s antitumor activity in vivo. Cisplatin 62-71 thymoma viral proto-oncogene 1 Mus musculus 37-40 23095324-4 2013 EXPERIMENTAL DESIGN: Using a genetically engineered mouse model of ovarian endometrioid adenocarcinoma (OEA) in combination with molecular-imaging technologies, we studied the activation of the AKT serine/threonine kinase in response to long-term cisplatin therapy. Cisplatin 247-256 thymoma viral proto-oncogene 1 Mus musculus 194-197 22760211-3 2012 Our previous study has demonstrated that NF-kappaB and Akt cooperatively blunt cytotoxicity induced by cisplatin or etopside in different types of cancer cells in vitro, indicating that the concurrent blocking of these pathways may effectively improve the anticancer efficacy of anticancer therapeutics. Cisplatin 103-112 thymoma viral proto-oncogene 1 Mus musculus 55-58 22760211-4 2012 In this study, we further investigated the effect of concurrent blockade of NF-kappaB and Akt on the anticancer activity of cisplatin in vivo in a xenograft tumor model. Cisplatin 124-133 thymoma viral proto-oncogene 1 Mus musculus 90-93 22760211-6 2012 The resultant cells with concurrent NF-kappaB and Akt blockade were significantly more sensitive to cisplatin-induced cell death in vitro. Cisplatin 100-109 thymoma viral proto-oncogene 1 Mus musculus 50-53 22760211-7 2012 Consistently, tumors derived from cells with the concurrent blockade of NF-kappaB and Akt were much more sensitive to cisplatin compared with those derived from cells with individual blockage of NF-kappaB or Akt in a nude mouse xenograft tumor model. Cisplatin 118-127 thymoma viral proto-oncogene 1 Mus musculus 86-89 22760211-9 2012 These results show for the first time that the concurrent blockage of the NF-kappaB and Akt pathways cooperatively potentiates the antitumor activity of cisplatin in vivo, indicating that this strategy may be potentially useful for clinical anticancer therapy. Cisplatin 153-162 thymoma viral proto-oncogene 1 Mus musculus 88-91 22096562-8 2011 Moreover, Pyk2 overexpressing HCC transfectants had a higher survival rate under cisplatin treatment by up-regulation of AKT phosphorylation. Cisplatin 81-90 thymoma viral proto-oncogene 1 Mus musculus 121-124 21074548-0 2011 Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Cisplatin 0-9 thymoma viral proto-oncogene 1 Mus musculus 72-75 21074548-3 2011 Within 24h of 50 muM cisPt administration, C2C12 myotubes displayed unchanged cell viability but showed a subset of hallmark signs typically recognized during atrophy, including severe reduction in body size, repression of Akt phosphorylation, transcriptional up-regulation of atrophy-related genes, such as atrogin-1, gabarap, beclin-1 and bnip-3, and loss of myogenic markers. Cisplatin 21-26 thymoma viral proto-oncogene 1 Mus musculus 223-226 21074548-4 2011 As a consequence, proteasomal activity and formation of autophagosomes were remarkably increased in cisPt-treated myotubes, but forced stimulation of Akt pathway, as obtained through insulin administration or delivery of a constitutively activated Akt form, was sufficient to counter the cisPt-induced protein breakdown, leading to rescue of atrophic size. Cisplatin 100-105 thymoma viral proto-oncogene 1 Mus musculus 248-251 21074548-5 2011 Overall, these results indicate that cisPt induces atrophy of C2C12 myotubes via activation of proteasome and autophagy systems, suggesting that the Akt pathway represents one sensitive target of cisPt molecular action in skeletal muscle. Cisplatin 37-42 thymoma viral proto-oncogene 1 Mus musculus 149-152 22096562-13 2011 CONCLUSIONS: Our results may suggest a new evidence of Pyk2 on promoting cisplatin resistance of HCC cells through preventing cell apoptosis, activation of AKT pathway and upregulation of drug resistant genes. Cisplatin 73-82 thymoma viral proto-oncogene 1 Mus musculus 156-159 20506484-6 2010 Furthermore, we have observed an additive effect of FTY720 in killing gastric cancer cells when in combination with Cisplatin, partly through PTEN-mediated Akt/MDM2 inhibition. Cisplatin 116-125 thymoma viral proto-oncogene 1 Mus musculus 156-159